Abstract
We evaluated the efficacy and safety of nimesulide (100 mg orally twice daily for > 48 hours) in a pilot series of five women (two with twin pregnancies) at 24 +6 weeks (range 21 +3–27 +2) in preterm labour which was unresponsive to intravenous ritodrine. Nimesulide therapy was continued for eight days (5–16) and was associated with a prolongation of pregnancy of 27 days (6–69). Oligohydramnios occurred in all seven fetuses after three to nine days of therapy, and in the five pregnancies that continued after discontinuation of nimesulide, it resolved within four days (2–7). None of the babies manifested permanent renal damage.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
